DuPont Shorts Stay Scarce as Stock Surges Into Results

DuPont de Nemours reports Q3 results on November 4 with short sellers having largely abandoned the trade. Short interest dropped 10% over the past week to roughly 4.4 million shares, just 1% of the free float, continuing a retreat from a mid-October peak near 5.2 million shares. That unwind closely mirrors the one described in our previous preview, and the direction has held.

The borrow market backs that picture up. Availability has expanded further to 6,694%, meaning there are roughly 67 shares available to lend for every one currently borrowed, up from around 5,500% a week ago. Cost to borrow collapsed to 0.058% from around 0.49% over the same stretch, its lowest level in at least six weeks. There is no meaningful short-side pressure on this stock going into the release.

The share price has been moving in the opposite direction. DuPont added 8.6% on Monday alone, and 11.5% over the past week, against a median peer gain of around 0.8%. That gap is striking. 3M, the closest US peer by correlation, gained 3.2% over the week. The stock has now risen 18% over the past month to $153.46, cutting the discount to the consensus analyst target of $166.12 to under 8%.

Analyst opinion shifted in two directions around the print. JP Morgan downgraded to Neutral and cut its target to $145 on October 9, the clearest expression of concern ahead of results. Since then, Barclays started coverage at Overweight with a $156 target, and Fermium Research raised its target to $160 yesterday while keeping a Buy rating. The debate centres on whether Healthcare and Water Technologies, which delivered mid-single-digit organic growth in Q2, can carry enough weight to offset continued softness in electronics, construction, and China-exposed segments. Bears point to execution risk on the spin-off strategy and a valuation that, even on a downside earnings scenario, still demands a multiple above 18x. Bulls cite strong free cash flow conversion, a buyback programme of more than $500 million this year, and optionality from roughly $1 billion available for bolt-on acquisitions.

Options positioning shifted noticeably on Monday. The put/call ratio jumped to 0.41, the highest reading in at least three weeks and nearly 1.8 standard deviations above its 20-day average. For most of October that ratio sat in a narrow band around 0.27 to 0.33. The move into protection was notable precisely because it came alongside the sharp price gain, suggesting some holders chose to hedge a rally rather than chase it.

The print will test whether the operational momentum in Healthcare and Water is sufficient to validate the stock's 18% one-month re-rating, or whether JP Morgan's more cautious read on the demand environment is the one the results bear out.